X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (805) 805
Publication (115) 115
Government Document (7) 7
Book Review (6) 6
Book Chapter (5) 5
Book / eBook (1) 1
Conference Proceeding (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (507) 507
female (465) 465
brca1/2 (452) 452
index medicus (423) 423
breast cancer (383) 383
oncology (373) 373
adult (308) 308
breast neoplasms - genetics (308) 308
middle aged (298) 298
mutation (277) 277
cancer (265) 265
brca1 (230) 230
genes, brca1 (220) 220
women (220) 220
ovarian-cancer (215) 215
ovarian cancer (212) 212
genes, brca2 (206) 206
aged (168) 168
genetic testing (167) 167
risk (166) 166
genetic aspects (162) 162
risk factors (158) 158
genetics & heredity (156) 156
ovarian neoplasms - genetics (153) 153
genetic predisposition to disease (146) 146
brca1 protein - genetics (133) 133
genetic counseling (131) 131
brca2 protein - genetics (128) 128
breast-cancer (110) 110
research (109) 109
genetic screening (101) 101
hereditary breast (100) 100
male (95) 95
brca1 protein (93) 93
gene mutations (90) 90
health aspects (86) 86
breast neoplasms - psychology (85) 85
human genetics (84) 84
analysis (82) 82
biomedicine (82) 82
heterozygote (77) 77
medicine & public health (76) 76
susceptibility (76) 76
breast neoplasms - diagnosis (75) 75
article (73) 73
genetics (73) 73
breast (72) 72
young adult (72) 72
brca1/2 mutation (66) 66
carriers (63) 63
family-history (63) 63
obstetrics & gynecology (63) 63
oncology, experimental (63) 63
brca1/2 mutations (62) 62
diagnosis (62) 62
epidemiology (62) 62
surgery (62) 62
communication (60) 60
genes (60) 60
germline mutations (60) 60
mutations (60) 60
surveys and questionnaires (60) 60
brca1/2 mutation carriers (59) 59
impact (59) 59
skin and connective tissue diseases (58) 58
mutation carriers (57) 57
prevention (57) 57
risk assessment (57) 57
cancer research (54) 54
adolescent (52) 52
decision making (51) 51
families (51) 51
genetic research (51) 51
chemotherapy (50) 50
brca2 protein (49) 49
medical genetics (49) 49
public, environmental & occupational health (49) 49
care and treatment (48) 48
breast neoplasms - pathology (47) 47
germ-line mutation (47) 47
mammography (46) 46
survival (46) 46
aged, 80 and over (44) 44
health risk assessment (44) 44
retrospective studies (43) 43
age (42) 42
ethics (42) 42
family (42) 42
breast neoplasms - epidemiology (41) 41
prognosis (41) 41
public health (41) 41
genetic predisposition to disease - psychology (40) 40
gynecology (40) 40
tumors (40) 40
clinical psychology (39) 39
poly polymerase (39) 39
carcinoma (38) 38
mastectomy (38) 38
breast neoplasms - prevention & control (37) 37
surveillance (37) 37
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (754) 754
French (24) 24
Polish (10) 10
German (8) 8
Russian (8) 8
Japanese (7) 7
Korean (6) 6
Chinese (3) 3
Italian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 06/2019, Volume 105, Issue 6, pp. 1492 - 1500
Olaparib is a poly ADP‐ribose polymerase inhibitor that induces synthetic lethality in tumors with deficient homologous recombination repair. Population... 
PHARMACOLOGY & PHARMACY | BRCA1/2 MUTATION | MAINTENANCE THERAPY | RELAPSED OVARIAN-CANCER
Journal Article
Oncotarget, ISSN 1949-2553, 04/2018, Volume 9, Issue 25, pp. 17501 - 17511
Checkpoint molecules such as programmed cell death protein-1 (PD-1) and its ligand PD-L1 are critically required for tumor immune escape. The objective of this... 
IFNγ | PD-L1 | BRCA1/2 | PD-1 | Ovarian cancer
Journal Article
Journal of Genetic Counseling, ISSN 1059-7700, 12/2018, Volume 27, Issue 6, pp. 1417 - 1427
Men with a germline pathogenic BRCA1 or BRCA2 variant have increased risks for developing breast, pancreatic, prostate, and melanoma cancers, but little is... 
BRCA1/2 | Uncertainty management theory | Men | Hereditary cancer risk
Journal Article
The Oncologist, ISSN 1083-7159, 07/2019, Volume 24, Issue 7, pp. e475 - e479
Inherited mutations in the breast cancer susceptibility genes BRCA1 and BRCA2 confer a high risk of breast and ovarian cancer. This article reports on the... 
BRCA1/2 | Hereditary breast cancer | Afro‐Colombians | Founder mutations | Afro-Colombians | WOMEN | 2 | ONCOLOGY | HEREDITARY BREAST | BRCA1
Journal Article
Japanese Journal of Clinical Oncology, ISSN 0368-2811, 03/2016, Volume 46, Issue 3, pp. 254 - 259
Journal Article
Annals of Oncology, ISSN 0923-7534, 01/2018, Volume 29, Issue 1, pp. 237 - 243
Abstract Background Preclinical evidence suggests a possible negative impact of deleterious BRCA mutations on female fertility. However, limited and rather... 
BRCA1/2 | Ovarian tissue cryopreservation | Breast cancer | Fertility | Oocyte cryopreservation | Anti-Mullerian hormone | RISKS | ONCOLOGY | anti-Mullerian hormone | fertility | GUIDELINES | breast cancer | OVARIAN | oocyte cryopreservation | ovarian tissue cryopreservation | PREGNANCY ISSUES | CARRIERS
Journal Article
Journal of the National Comprehensive Cancer Network : JNCCN, ISSN 1540-1405, 01/2019, Volume 17, Issue 1, pp. 7 - 11
Cowden syndrome (CS) is an autosomal dominant mendelian disease related to germline pathogenic variants affecting the PTEN-gene. CS is characterized by... 
BRCA1/2 | RISKS | ONCOLOGY | MOLECULAR PATHOGENESIS | LYNCH SYNDROME | MUTATIONS | CANCER
Journal Article
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, ISSN 0027-8874, 07/2019, Volume 111, Issue 7, pp. 684 - 694
Background Vitamins are among the most frequently used supplements (48% of US adults). However, little is known about contributions of genetic variation to... 
VAL158MET POLYMORPHISM | CATECHOL-O-METHYLTRANSFERASE | VITAMIN-E | LOW-DOSE ASPIRIN | MESSENGER-RNA | ONCOLOGY | CARDIOVASCULAR-DISEASE | RISK | BRCA1/2 VARIANTS | COOCCURRENCE | ASSOCIATION
Journal Article
Drugs, ISSN 0012-6667, 12/2018, Volume 78, Issue 18, pp. 1939 - 1946
Talazoparib (TALZENNA™) is an oral inhibitor of the polyadenosine 5′-diphosphoribose polymerase (PARP) enzymes, which play a critical role in repairing DNA... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | BREAST-CANCER | GERMLINE BRCA1/2 MUTATIONS | PHARMACOLOGY & PHARMACY | TOXICOLOGY | INHIBITOR | PHASE-I
Journal Article
Journal Article
Asian Pacific Journal of Cancer Prevention, ISSN 1513-7368, 2016, Volume 17, Issue 4, pp. 1987 - 1991
Journal Article